Effects of simultaneous aortocaval occlusion on oxygen consumption in patients.
The effects of simultaneous occlusion of the thoracic aorta and inferior vena cava on oxygen consumption (V O 2) have not yet been reported in humans. Ten patients (all ASA II) needed such simultaneous occlusion to allow hypoxic abdominal perfusion in the treatment of pancreatic cancer. With the development of the PhysioFlex anaesthesia machine for closed-circuit anaesthesia, intra-operative real-time curves of V O 2 became available. Thus, we can continuously measure F I O 2, V E, V O 2, and air consumption. By placing a pulmonary artery catheter, we could also intermittently calculate D O 2 during the several phases of the perfusion procedure. Immediately after the simultaneous aortocaval occlusion started, V O 2 decreased by 35% (68 ml min-1 m-2) and D O 2 decreased below the critical value of 330 ml min-1 m-2. At reperfusion, repayment of the oxygen debt was by a two-stage pattern: a fast repayment stage with an increase of about 65% was followed by a slow repayment stage of 14% increase (values compared to steady state). Oxygen consumption in women was found to be significantly lower than in men (P = 0.02), with significant variation between the sexes during different stages of the procedure. The oxygen debt was not completely repaid by the end of the procedure. We conclude that the significant variation found in oxygen consumption will have consequences while performing low-flow anaesthesia, that additional oxygen supply during the recovery period because of the initially incomplete repayment of oxygen debt may be useful and that studies on oxygen consumption must present gender-specific data because of the gender-dependent variation found in oxygen consumption.
Hofland
Jan
J
Departments of Anaesthesiology and Surgical Oncology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands. j.hofland@amc.uva.nl
Tenbrinck
Robert
R
Eggermont
Alexander M M
AM
Eijck
Casper H J
CH
Gommers
Diederik
D
Erdmann
Wilhelm
W
D000970:Antineoplastic Agents / Q000008:administration & dosage; D001013:Aorta, Thoracic / Q000503:physiopathology*; D001682:Biological Availability; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003250:Constriction; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D012119:Respiration; D012727:Sex Characteristics; D014682:Vena Cava, Inferior / Q000503:physiopathology*
D000970:Antineoplastic Agents; D010100:Oxygen